FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947362805> ?p ?o ?g. }

• W2947362805 abstract "Background The pathogenesis of large vessel vasculitis (LVV) such as Takayasu arteritis (TAK) and giant cell arteritis (GCA) consists of the immune abnormalities including the interaction between vascular dendritic cells, macrophages and T cells. It is reported that genetic polymorphisms in the immune-modulating cytokine genes such as IL6 and IL12B are associated with LVV. However, little is known about pathological immune cell subsets targeted by immunosuppressants and/or molecular-target therapy such as IL-6 blockade. Objectives The aim of this study was to assess the relationship between the phenotype of peripheral immune cells with clinical manifestations and responsiveness to the treatment in patients with LVV. Methods Peripheral blood mononuclear cells were obtained from 22 patients with active LVV (TAK 7, GCA 15) and 19 healthy donors (HD). All patients were treated with high dose glucocorticoid (GC). The study included the patients treated with immunosuppressive agents such as azathioprine and methotrexate (n=8) or with anti-IL-6 receptor antibody tocilizumab (n=7). The blood samples were taken at baseline and week 24 after treatment. The peripheral immune cell subset was defined based on comprehensive 8-color flow cytometric analysis for human immune system termed “the Human Immunology Project” by NIH and FOCIS (1), and the correlation with clinical characteristics and responsiveness to the therapies were evaluated. Results The proportion of CD3+CD4+CXCR3-CCR6+CD38+HLA-DR+ activated Th17 cells and CD3+CD4+CXCR5+ICOS+CD38+ activated Tfh cells in patients with TAK and that of activated Th17 cells and CD19+CD20+CD27-IgD- double negative effector B cells in patients with GCA were significantly higher compared with HD. At baseline, the frequency of activated Tfh cells showed positive correlation and that of CD4+CCR4+CD25+CD127low T regulatory (Treg) cells showed negative correlation with disease activity scores such as Indian Takayasu Activity Index (ITAS)2010 (2) and ITAS.A (CRP) in both TAK and GCA. The immunosuppressive therapy improved the disease activity in all patients. The frequency of activated Tfh cells was reduced by 24-week treatment with high dose GC and immunosuppressants in TAK and GCA. However, the frequency of Th17 cells was not changed by those treatments. Of note, tocilizumab decreased the proportion of activated Th17 cells and increased the proportion of Treg cells in both TAK and GCA. Conclusion The results indicated that the abnormal T cell differentiation correlated with disease activity of LVV. Although Tfh cell activation was improved, Th17 cell activation was not changed by the conventional immunosuppressive agents. By contrast, tocilizumab reduced Th17 cells and increased Treg cells, indicating that IL-6 blockade may correct the impaired balance of Th17 and Treg cells in patients with LVV. References [1] Maecker HT, et al. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol2012; 12: 191-200. [2] Misra R, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013; 52: 1795-801. Disclosure of Interests Shingo Nakayamada Grant/research support from: Mitsubishi-Tanabe, Takeda, Novartis and MSD, Speakers bureau: Bristol-Myers, Sanofi, Abbvie, Eisai, Eli Lilly, Chugai, Asahi-kasei and Pfizer, Yusuke Miyazaki: None declared, Hiroko Yoshinari: None declared, Akio Kawabe: None declared, Ippei Miyagawa: None declared, Satoshi Kubo Speakers bureau: Bristol-Myers, Pfizer, Takeda, and Eli Lilly, Shunsuke Fukuyo: None declared, Shigeru Iwata: None declared, Kazuhisa Nakano: None declared, Yoshiya Tanaka Grant/research support from: Abbvie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, MSD, Ono, Taisho-Toyama, Takeda, Speakers bureau: Abbvie, Asahi-kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Glaxo-Smithkline, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer Japan Inc, Sanofi, Takeda, UCB, YL Biologics" @default.
• W2947362805 created "2019-06-07" @default.
• W2947362805 creator A5006691121 @default.
• W2947362805 creator A5050991104 @default.
• W2947362805 creator A5057795958 @default.
• W2947362805 creator A5060337871 @default.
• W2947362805 creator A5061676124 @default.
• W2947362805 creator A5061703808 @default.
• W2947362805 creator A5067195079 @default.
• W2947362805 creator A5068524115 @default.
• W2947362805 creator A5073326633 @default.
• W2947362805 date "2019-06-01" @default.
• W2947362805 modified "2023-09-23" @default.
• W2947362805 title "SAT0026 IMPACT OF TOCILIZUMAB ON IMMUNE PHENOTYPES IN PATIENTS WITH LARGE VESSEL VASCULITIS" @default.
• W2947362805 doi "https://doi.org/10.1136/annrheumdis-2019-eular.2240" @default.
• W2947362805 hasPublicationYear "2019" @default.
• W2947362805 type Work @default.
• W2947362805 sameAs 2947362805 @default.
• W2947362805 citedByCount "0" @default.
• W2947362805 crossrefType "proceedings-article" @default.
• W2947362805 hasAuthorship W2947362805A5006691121 @default.
• W2947362805 hasAuthorship W2947362805A5050991104 @default.
• W2947362805 hasAuthorship W2947362805A5057795958 @default.
• W2947362805 hasAuthorship W2947362805A5060337871 @default.
• W2947362805 hasAuthorship W2947362805A5061676124 @default.
• W2947362805 hasAuthorship W2947362805A5061703808 @default.
• W2947362805 hasAuthorship W2947362805A5067195079 @default.
• W2947362805 hasAuthorship W2947362805A5068524115 @default.
• W2947362805 hasAuthorship W2947362805A5073326633 @default.
• W2947362805 hasBestOaLocation W29473628051 @default.
• W2947362805 hasConcept C10205521 @default.
• W2947362805 hasConcept C126322002 @default.
• W2947362805 hasConcept C12823836 @default.
• W2947362805 hasConcept C13373296 @default.
• W2947362805 hasConcept C137061746 @default.
• W2947362805 hasConcept C159654299 @default.
• W2947362805 hasConcept C159912055 @default.
• W2947362805 hasConcept C167672396 @default.
• W2947362805 hasConcept C18031839 @default.
• W2947362805 hasConcept C202751555 @default.
• W2947362805 hasConcept C203014093 @default.
• W2947362805 hasConcept C25532541 @default.
• W2947362805 hasConcept C2776015282 @default.
• W2947362805 hasConcept C2776090121 @default.
• W2947362805 hasConcept C2776712624 @default.
• W2947362805 hasConcept C2777178219 @default.
• W2947362805 hasConcept C2777575956 @default.
• W2947362805 hasConcept C2778957590 @default.
• W2947362805 hasConcept C2779134260 @default.
• W2947362805 hasConcept C28328180 @default.
• W2947362805 hasConcept C54355233 @default.
• W2947362805 hasConcept C55493867 @default.
• W2947362805 hasConcept C71924100 @default.
• W2947362805 hasConcept C86803240 @default.
• W2947362805 hasConcept C8891405 @default.
• W2947362805 hasConceptScore W2947362805C10205521 @default.
• W2947362805 hasConceptScore W2947362805C126322002 @default.
• W2947362805 hasConceptScore W2947362805C12823836 @default.
• W2947362805 hasConceptScore W2947362805C13373296 @default.
• W2947362805 hasConceptScore W2947362805C137061746 @default.
• W2947362805 hasConceptScore W2947362805C159654299 @default.
• W2947362805 hasConceptScore W2947362805C159912055 @default.
• W2947362805 hasConceptScore W2947362805C167672396 @default.
• W2947362805 hasConceptScore W2947362805C18031839 @default.
• W2947362805 hasConceptScore W2947362805C202751555 @default.
• W2947362805 hasConceptScore W2947362805C203014093 @default.
• W2947362805 hasConceptScore W2947362805C25532541 @default.
• W2947362805 hasConceptScore W2947362805C2776015282 @default.
• W2947362805 hasConceptScore W2947362805C2776090121 @default.
• W2947362805 hasConceptScore W2947362805C2776712624 @default.
• W2947362805 hasConceptScore W2947362805C2777178219 @default.
• W2947362805 hasConceptScore W2947362805C2777575956 @default.
• W2947362805 hasConceptScore W2947362805C2778957590 @default.
• W2947362805 hasConceptScore W2947362805C2779134260 @default.
• W2947362805 hasConceptScore W2947362805C28328180 @default.
• W2947362805 hasConceptScore W2947362805C54355233 @default.
• W2947362805 hasConceptScore W2947362805C55493867 @default.
• W2947362805 hasConceptScore W2947362805C71924100 @default.
• W2947362805 hasConceptScore W2947362805C86803240 @default.
• W2947362805 hasConceptScore W2947362805C8891405 @default.
• W2947362805 hasLocation W29473628051 @default.
• W2947362805 hasOpenAccess W2947362805 @default.
• W2947362805 hasPrimaryLocation W29473628051 @default.
• W2947362805 hasRelatedWork W2314178517 @default.
• W2947362805 hasRelatedWork W2314786701 @default.
• W2947362805 hasRelatedWork W2316374243 @default.
• W2947362805 hasRelatedWork W2320571795 @default.
• W2947362805 hasRelatedWork W2326880871 @default.
• W2947362805 hasRelatedWork W2327811983 @default.
• W2947362805 hasRelatedWork W2335309349 @default.
• W2947362805 hasRelatedWork W2551229842 @default.
• W2947362805 hasRelatedWork W2755374546 @default.
• W2947362805 hasRelatedWork W2946866952 @default.
• W2947362805 hasRelatedWork W2949639204 @default.
• W2947362805 hasRelatedWork W2950659033 @default.
• W2947362805 hasRelatedWork W2950678611 @default.
• W2947362805 hasRelatedWork W2951192946 @default.
• W2947362805 hasRelatedWork W2952519748 @default.
• W2947362805 hasRelatedWork W2952584299 @default.
• W2947362805 hasRelatedWork W3034658459 @default.

• next